Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563)
😃Good
Catalog No. TMAH-01070
Alias Spike glycoprotein, S glycoprotein, Peplomer protein, E2
Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563) is an antibody targeting SARS-CoV-2 Spike RBD Nanobody. Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563) can be used in ELISA, GICA, Neutralising.
Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563)
Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563)
😃Good
Catalog No. TMAH-01070Alias Spike glycoprotein, S glycoprotein, Peplomer protein, E2
Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563) is an antibody targeting SARS-CoV-2 Spike RBD Nanobody. Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563) can be used in ELISA, GICA, Neutralising.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 50 μL | $419 | 7-10 days | |
| 100 μL | $699 | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Antibody Type: Recombinant Monoclonal Application: ELISA, GICA Reactivity: Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) |
| Alias | Spike glycoprotein, S glycoprotein, Peplomer protein, E2 |
| Ig Type | VHH fusion with human IgG1 Fc |
| Clone | 5A563 |
| Reactivity | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) |
| Verified Activity | 1. The Binding Activity of SARS-CoV-2 Spike RBD Nanobody with SARS-CoV-2-S1-RBD Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 2 μg/ml can bind SARS-CoV-2 Spike RBD Nanobody, the EC50 is 0.8674 ng/ml. 2. In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (TMAH-01070) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good. 3. SARS-CoV-2 Spike RBD Nanobody (TMAH-01070) competed with ACE2-HRP conjugate for binding to SARS-CoV-2-S1-RBD. The binding signal of SARS-CoV-2-S1-RBD and ACE2-HRP conjugate was gradually reduced as the SARS-CoV-2 Spike RBD Nanobody concentrations increased. It indicated that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of this SARS-CoV-2 Spike RBD Nanobody is 1.296 nM. 4. SARS-CoV-2 Spike RBD Nanobody (TMAH-01070) competitively prevented SARS-CoV-2-S1-RBD from binding to ACE2-HRP conjugate. The inhibition efficacy of the SARS-CoV-2-S1-RBD/ACE2 binding was positively proportionally to the SARS-CoV-2 Spike RBD Nanobody concentrations. It showed that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of this SARS-CoV-2 Spike RBD Nanobody is 0.1074 μg/ml. 5. SARS-CoV-2 Spike protein RBD His/Sumostar Tag captured on COOH chip binding to the SARS-CoV-2 Spike RBD Nanobody (TMAH-01070), increases the local refractive index (RI), leading to a red shift of the LSPR peak position. The higher concentrations of SARS-CoV-2 Spike RBD Nanobody, the larger the wavelength shift. The detected affinity constant of SARS-CoV-2 Spike protein RBD/SARS-CoV-2 Spike RBD Nanobody binding is 28.2nM. 6. ELISA: Immobilize various types of SARS proteins at concentration of 2μg/ml on solid substrate, then react with SARS-CoV-2 Spike RBD Nanobody at concentration of 100μg/ml, 10μg/ml and 1μg/ml. It shows the SARS-CoV-2 Spike RBD Nanobody (TMAH-01070) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with MERS-CoV, SARS-CoV, HCoV-OC43 or HCoV-229E. |
| Application | ELISA, GICA |
| Recommended Dose | ELISA:1:10000-1:100000; GICA:1:10000-1:40000; Neutralising:1:100-1:10000. |
| Antibody Type | Monoclonal |
| Subcellular Localization | Virion membrane; Single-pass type I membrane protein. Host endoplasmic reticulum-Golgi intermediate compartment membrane; Single-pass type I membrane protein. Host cell membrane; Single-pass type I membrane protein. |
| Construction | Recombinant Antibody |
| Purification | Affinity-chromatography |
| Appearance | Liquid |
| Formulation | Preservative: 0.03% Proclin 300. Constituents: 50% Glycerol, 0.01M PBS, PH 7.4. |
| Research Background | attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein. Binding to host NRP1 and NRP2 via C-terminal polybasic sequence enhances virion entry into host cell. This interaction may explain virus tropism of human olfactory epithelium cells, which express high level of NRP1 and NRP2 but low level of ACE2. The stalk domain of S contains three hinges, giving the head unexpected orientational freedom. Uses human TMPRSS2 for priming in human lung cells which is an essential step for viral entry. Can be alternatively processed by host furin. Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes. mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis. May down-regulate host tetherin (BST2) by lysosomal degradation, thereby counteracting its antiviral activity. |
| Conjucates | Unconjugated |
| Others Formats | Biotin/FITC/HRP |
| Antibody Types Available | 4 |
| Immunogen | Recombinant Protein: Human Novel Coronavirus Spike glycoProtein(S) (319-541aa) |
| Antigen Species | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) |
| Uniprot ID | |
| Biology Area | Microbiology |
Stability & Storage
| Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Transport | Shipping with blue ice. |
Sci Citations
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563) | purchase Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563) | Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563) cost | order Anti-SARS-CoV-2 Spike RBD Nanobody Antibody (5A563)
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.